MRK – merck & company, inc. (new) (US:NASDAQ)
Stock Stats
News
4/2
04:04 pm
mrk
Low
MRK Deadline: MRK Purchasers with Losses in Excess of $100K Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
4/2
03:17 pm
mrk
Low
MRK DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK
4/2
12:00 pm
mrk
Low
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
4/2
09:55 am
mrk
Low
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
4/2
09:13 am
mrk
Low
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
2/4/2025
06:30 am
MRK
-9.7%
BEAT
2/4/2025
06:30 am
MRK
-5.0%
BEAT
2/4/2025
06:30 am
MRK
-2.6%
BEAT
2/4/2025
06:30 am
MRK
-3.6%
BEAT
2/18
07:33 am
Downgrades
Buy
Hold
Deutsche Bank
Low
0.2%
2/18
07:33 am
Downgrades
Buy
Hold
Deutsche Bank
Low
0.2%
2/18
06:08 am
Downgrades
BUY
HOLD
DEUTSCHE BANK
Low
0.7%
2/18
06:08 am
Downgrades
BUY
HOLD
DEUTSCHE BANK
Low
0.7%
2/12
10:24 am
Maintains
Buy
Buy
Guggenheim
Low
-0.9%
4/2
09:57 am
mrk
Low
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Seidman Christine E
4/2
09:53 am
mrk
Low
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: GLOCER THOMAS H
4/2
09:50 am
mrk
Low
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Coe Mary Ellen
3/6
02:09 pm
mrk
Low
Form SCHEDULE 13G/A Merck & Co., Inc. Filed by: VANGUARD GROUP INC
2/20
04:02 pm
mrk
Low
Form 4 Merck & Co., Inc. For: Feb 19 Filed by: Oosthuizen Johannes Jacobus
Show more
Top News Gainers
3/28 Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies 7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
Top News Decliners
3/13 Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily] -8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3